121-Unlock Immunotherapy Resistance by CXCR4 partial agonist
This article reports on a novel immunotherapy strategy for gastric and other gastrointestinal cancers using TFF2-MSA, a CXCR4 partial agonist peptide, in combination with anti-PD-1 treatment. Researchers demonstrate that TFF2-MSA synergistically enhances anti-PD-1 efficacy by selectively reducing immunosuppressive neutrophils (PMN-MDSCs), particularly the CXCR4-highly-expressing Hdc-GFP+ subset, in the tumor microenvironment and circulation. Mechanistically, TFF2-MSA acts systemically to suppress cancer-driven granulopoiesis in the bone marrow, contrasting with traditional CXCR4 antagonists…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.